Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization
10.3760/cma.j.issn.0253-2727.2021.01.005
- VernacularTitle:普乐沙福联合G-CSF在浆细胞疾病自体造血干细胞动员中的有效性及安全性
- Author:
Wenbing DUAN
1
;
Xuelin DOU
;
Wen LEI
;
Fengrong WANG
;
Xiaojun HUANG
;
Jin LU
Author Information
1. 北京大学人民医院、北京大学血液病研究所，国家血液系统疾病临床医学研究中心 100044
- Keywords:
Plasma cell disease;
Autologous hematopoietic stem cell mobilization;
Plerixafor
- From:
Chinese Journal of Hematology
2021;42(1):21-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effect and safety of plerixafor combined with G-CSF mobilization in plasma cell disease.Methods:The clinical baseline data, success rate of collection, and adverse reactions of consecutive cases of plasma cell disease were analyzed retrospectively, where the patients received plerixafor combined with G-CSF for autologous hematopoietic stem cell mobilization in Peking University People's Hospital from January 2018 to December 2019.Results:Forty-nine patients with plasma disease were included, of which 39 (79.6% ) were multiple myeloma, 8 (16.3% ) were amyloidosis, and 2 (4.1% ) were monoclonal gammopathy of renal significance. A total of 16 patients (32.7% ) had renal insufficiency, and 7 patients (14.3% ) had previous collection failure. The median times of apheresis was 1 (1-3) , median days of apheresis was 2 (1-3) days, 47 patients (95.9% ) were successfully collected for once, and the success rate of collection for twice was 100% after using plerixafor for mobilization. In 16 patients with renal insufficiency, collection was successful in 5 patients (31.3% ) on the first day, while aphresis was required in 8 patients (50% ) on the second day and 3 (18.8% ) on the third day. The main adverse reactions were fatigue, insomnia, abdominal pain, diarrhea, dizziness, and arthralgia. A total of 37 patients underwent autologous hematopoietic stem cell transplantation with 11 (8-13) days for neutrophil engraftment, and 11 (9-26) days for platelet engraftment.Conclusions:Plerixafor combined with G-CSF has a high success rate in mobilizaion of autologous hematopoietic stem cells in patients with plasma cell disease with minimum side effects, even in patients with renal insufficiency.
